|Targets||Glucagon-Like Peptide 1 (GLP-1)|
|Description||BPI-3016 is an analogue of human glucagon-like peptide 1 (hGLP-1) that has a long effect on type 2 diabetes mellitus. In vitro, BPI-3016 exhibited an affinity to GLP receptors and promotes cAMP production. In vivo, the half-life of BPI-3016 was 95h after single dosing in pharmacokinetic studies in diabetic cynomolgus monkey models.|
|Brife Description||analogue of human glucagon-like peptide 1 (hGLP-1), type 2 diabetes mellitus|
|Application||the treatment of type 2 diabetes|
|Current Developer||Betta Pharmaceuticals|
Semaglutide is an agonist of glucagon-like peptide-1 (GLP-1) receptor that is developed to treat type 2 diabetes. It reduces blood sugar via increasing the prod...
BPI-3016 is an analogue of human glucagon-like peptide 1 (hGLP-1) that has a long effect on type 2 diabetes mellitus. In vitro, BPI-3016 exhibited an affinity t...
GLP-1 (7-37) acetate
GLP-1 (7-37) acetate is an insulinotropic peptide generated from the precursor peptide GLP-1(1-37). It is a potent stimulator of insulin secretion at concentrat...
Exenatide, naturally occured in the saliva of the Gila monster, an incretin mimetic that has glucoregulatory effect. As a glucagon-like peptide-1 (GLP-1) recept...